Literature DB >> 33269185

Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Khaled S Allemailem1,2, Ahmad Almatroudi1, Mohammed A Alsahli1, Ghaiyda Talal Basfar3, Faris Alrumaihi1, Arshad Husain Rahmani1, Amjad Ali Khan2.   

Abstract

The innovative discovery of aptamers was based on target-specific treatment in clinical diagnostics and therapeutics. Aptamers are synthetic, single-stranded oligonucleotides, simply described as chemical antibodies, which can bind to diverse targets with high specificity and affinity. Aptamers are synthesized by the SELEX technique, and possess distinctive properties as small size (10-50 kDa), higher stability, easy manufacture and less immunogenicity. These oligonucleotides are easily degraded by nucleases, so require some important modifications like capping and incorporation of modified nucleotides. RNA aptamers can be modified chemically on 2' positions using -NH3, -F, -deoxy, or -OMe groups to enhance their nuclease resistance. Aptamers have been employed for multiple purposes, as direct drugs or aptamer-drug conjugates targeted against different diseased cells. Different aptamer-conjugated nanovehicles (e.g., micelles, liposomes, silica nano-shells) have been designed to transport diverse anticancer-drugs like doxorubicin and cisplatin in bulk to minimize systemic cytotoxicity. Some drug-loaded nanovehicles (up to 97% loading capacity) and conjugated with specific aptamer resulted in more than 60% tumor inhibition as compared to unconjugated drug-loaded nanovehicles which showed only 31% cancer inhibition. In addition, aptamers have been widely used in basic research, food safety, environmental monitoring, clinical diagnostics and therapeutics. Different FDA-approved RNA and DNA aptamers are now available in the market, used for the treatment of diverse diseases, especially cancer. These aptamers include Macugen, Pegaptanib, etc. Despite a good progress in aptamer use, the present-day chemotherapeutics and drug targeting systems still face great challenges. Here in this review article, we are discussing nucleic acid aptamers, preparation, role in the transportation of different nanoparticle vehicles and their applications as therapeutic agents. © King Abdulaziz City for Science and Technology 2020.

Entities:  

Keywords:  Aptamosomes; Drug delivery; Micelles; Nucleic acid aptamers; SELEX; Therapeutics

Year:  2020        PMID: 33269185      PMCID: PMC7686427          DOI: 10.1007/s13205-020-02546-1

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.406


  184 in total

1.  An allosteric synthetic DNA.

Authors:  L Wu; J F Curran
Journal:  Nucleic Acids Res       Date:  1999-03-15       Impact factor: 16.971

2.  A Versatile Approach Towards Nucleobase-Modified Aptamers.

Authors:  Fabian Tolle; Gerhard M Brändle; Daniel Matzner; Günter Mayer
Journal:  Angew Chem Int Ed Engl       Date:  2015-07-23       Impact factor: 15.336

3.  Imino proton exchange rates imply an induced-fit binding mechanism for the VEGF165-targeting aptamer, Macugen.

Authors:  Joon-Hwa Lee; Fiona Jucker; Arthur Pardi
Journal:  FEBS Lett       Date:  2008-05-15       Impact factor: 4.124

4.  Potent 2'-amino-, and 2'-fluoro-2'-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor.

Authors:  N C Pagratis; C Bell; Y F Chang; S Jennings; T Fitzwater; D Jellinek; C Dang
Journal:  Nat Biotechnol       Date:  1997-01       Impact factor: 54.908

5.  RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.

Authors:  Si Eun Baek; Kwang Hyun Lee; Yong Serk Park; Deok-Kun Oh; Sangtaek Oh; Keun-Sik Kim; Dong-Eun Kim
Journal:  J Control Release       Date:  2014-10-24       Impact factor: 9.776

6.  Intracellular expression of the T-cell factor-1 RNA aptamer as an intramer.

Authors:  Kang Hyun Choi; Min Woo Park; Seung Yeon Lee; Mi-Ya Jeon; Mee Young Kim; Hee Kyu Lee; Jaehoon Yu; Hong-Jin Kim; Kyungsook Han; Heviran Lee; Keerang Park; Woong June Park; Sunjoo Jeong
Journal:  Mol Cancer Ther       Date:  2006-09       Impact factor: 6.261

7.  Cancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Homotypic Tumors.

Authors:  Huiping Sun; Jinghan Su; Qingshuo Meng; Qi Yin; Lingli Chen; Wangwen Gu; Pengcheng Zhang; Zhiwen Zhang; Haijun Yu; Siling Wang; Yaping Li
Journal:  Adv Mater       Date:  2016-09-15       Impact factor: 30.849

8.  Particle display: a quantitative screening method for generating high-affinity aptamers.

Authors:  Jinpeng Wang; Qiang Gong; Nupur Maheshwari; Michael Eisenstein; Mary Luz Arcila; Kenneth S Kosik; H Tom Soh
Journal:  Angew Chem Int Ed Engl       Date:  2014-03-18       Impact factor: 15.336

9.  Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth.

Authors:  Sorah Yoon; Kai-Wen Huang; Vikash Reebye; Duncan Spalding; Teresa M Przytycka; Yijie Wang; Piotr Swiderski; Lin Li; Brian Armstrong; Isabella Reccia; Dimitris Zacharoulis; Konstantinos Dimas; Tomokazu Kusano; John Shively; Nagy Habib; John J Rossi
Journal:  Mol Ther Nucleic Acids       Date:  2016-12-10

10.  One-step selection of Vaccinia virus-binding DNA aptamers by MonoLEX.

Authors:  Andreas Nitsche; Andreas Kurth; Anna Dunkhorst; Oliver Pänke; Hendrik Sielaff; Wolfgang Junge; Doreen Muth; Frieder Scheller; Walter Stöcklein; Claudia Dahmen; Georg Pauli; Andreas Kage
Journal:  BMC Biotechnol       Date:  2007-08-15       Impact factor: 2.563

View more
  3 in total

1.  Selection and identification of a novel ssDNA aptamer targeting human skeletal muscle.

Authors:  Shuming Sun; Han Liu; Yan Hu; Yanpeng Wang; Mingri Zhao; Yijun Yuan; Yafei Han; Yingying Jing; Jin Cui; Xiaoxiang Ren; Xiao Chen; Jiacan Su
Journal:  Bioact Mater       Date:  2022-05-27

Review 2.  Non-Coding RNAs in Tuberculosis Epidemiology: Platforms and Approaches for Investigating the Genome's Dark Matter.

Authors:  Ahmad Almatroudi
Journal:  Int J Mol Sci       Date:  2022-04-17       Impact factor: 6.208

Review 3.  Multi-Functional Liposome: A Powerful Theranostic Nano-Platform Enhancing Photodynamic Therapy.

Authors:  Xiamin Cheng; Jing Gao; Yang Ding; Yao Lu; Qiancheng Wei; Dezhi Cui; Jiali Fan; Xiaoman Li; Ershu Zhu; Yongna Lu; Qiong Wu; Lin Li; Wei Huang
Journal:  Adv Sci (Weinh)       Date:  2021-06-03       Impact factor: 16.806

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.